Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX
Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX
Long-term follow-up of subjects who received SB-318, SB-913, or SB-FIX in a previous trial
 and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled
 subjects will be followed for a total of up to 10 years following exposure to SB-318, SB-913,
 or SB-FIX.
Non-interventional, multi-center, long-term follow-up (LTFU) study of subjects dosed with
 SB-318 in the clinical study SB-318-1502, SB-913 in the clinical study SB-913-1602, and
 SB-FIX in clinical study SB-FIX-1501. All subjects dosed in the studies and completed at
 least 52 weeks post-infusion follow-up in their primary protocol will be offered to
 participate. Subjects who enroll will be monitored for a total of up to 10 years following
 exposure to the respective investigational products.
Inclusion Criteria:

 1. Subjects who received SB-318 under Study Protocol SB-318-1502, SB-913 under Study
 Protocol SB-913-1602, or SB-FIX under Study Protocol SB-FIX-1501

 2. Subjects who have provided consent to participate in the LTFU study.

 Exclusion Criteria:

 1. Unable to comply with study visit schedule or study visit procedures.

 2. Any other reason that, in the opinion of the Investigator or Medical Monitor, would
 render the subject unsuitable for participation in the study.